GSK in­vests $270M in­to vac­cine man­u­fac­tur­ing in Bel­gium

GSK is in­vest­ing about $270 mil­lion (€250 mil­lion) to build out and ex­pand its vac­cine man­u­fac­tur­ing fa­cil­i­ties in Wavre, Bel­gium.

The plant is ex­pect­ed to have two wings: one for pro­duc­ing its “non-live” vac­cines, in­clud­ing the new­ly ap­proved RSV vac­cine Arexvy and the shin­gles vac­cine Shin­grix, and the oth­er wing will make “live” vac­cines, in­clud­ing Var­il­rix for chick­en­pox and Pri­or­ix for measles.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER